
First-quarter acquisition activity lifts hopes for a big year
After a slow 2017, first-quarter biopharma acquisition activity could signal a turnaround.

M&A: 2017 proves snooze-worthy on the acquisition front
Pharma and biotech takeover activity slumps to a five-year low in 2017.